Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Property And Equipment Estimated Useful Lives

The estimated useful life of the different groups of property and equipment is as follows:


Asset Classification		Estimated useful life (in years)
Leasehold improvements		shorter of useful life or remaining life of the lease
Laboratory equipment		1 - 14
Office and computer equipment		1 - 15

Schedule of Fair Value Assumptions

Accordingly, the weighted-average fair value of the options granted during the years ended December 31, 2016 and 2015 was $1.00 and $1.87, respectively based on the following assumptions:


	Years Ended December 31,
	2016	2015
Risk free interest rate	1.13%-2.08%	1.47%-1.89%
Expected term	5.0 – 5.7 years	5.0 – 6.1 years
Dividend yield	—	—
Expected volatility	74.90%-76.00%	72.65%-75.07%

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense was recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows:


	Years Ended December 31,
	2016		2015
Research and development	$	599,138	$	379,066
General and administrative		1,306,118		785,567

Total stock-based compensation	$	1,905,256	$	1,164,633